专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5189147A Meterodimeric T lymphocyte receptor antibody 失效
标题翻译：甲基二聚体T淋巴细胞受体抗体
公开(公告)号：US5189147A
公开(公告)日：1993-02-23
申请号：US271216
申请日：1988-11-14
申请人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
发明人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
IPC分类号： A61K39/00 , C07K14/725
CPC分类号： C07K14/7051 , A61K39/00
摘要： Disclosed is a heterodimeric T lymphocyte receptor comprising an alpha and a beta subunit. Each subunit consists of a signal peptide, variable, joining, constant, transmembrane, and cytoplasmic regions. The two subunits are connected by a disulfide bond between cysteine residues located between the constant and transmembrane region.The structure, amino acid, and nucleotide sequence of the lymphocyte receptor were determined using cDNA cones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressedThe U.S. government has rights in this invention by virtue of Grant No. NIH-5-POl-CA28900-04, NIH-5-P30-CA14051-13 and the Arthritis Foundation.
摘要翻译：公开了包含α和β亚基的异二聚体T淋巴细胞受体。每个亚基由信号肽，可变，连接，恒定，跨膜和细胞质区域组成。两个亚基通过位于恒定区和跨膜区之间的半胱氨酸残基之间的二硫键连接。使用衍生自功能性鼠细胞毒性T淋巴细胞克隆的cDNA锥来确定淋巴细胞受体的结构，氨基酸和核苷酸序列。与这些cDNA相对应的基因在T细胞中特异性表达和重排，并且与免疫球蛋白V和C基因具有显着的序列同源性。 T细胞受体蛋白及其亚基都可以从cDNA克隆产生。蛋白质分子可以进一步用于生产T细胞克隆特异性抗体。

2. 发明申请

US20090124567A1 Influenza Therapeutic 审中-公开
标题翻译：流感治疗
公开(公告)号：US20090124567A1
公开(公告)日：2009-05-14
申请号：US12167593
申请日：2008-07-03
申请人： Jianzhu Chen , Herman N. Eisen , Qing Ge
发明人： Jianzhu Chen , Herman N. Eisen , Qing Ge
IPC分类号： A61K31/7052 , C07H21/00 , C12N5/00 , A61P31/16 , C12N15/63 , A01K67/033
CPC分类号： C12N15/1131 , A61K38/00 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12N2320/32 , C12N2799/021
摘要： The present invention provides methods and compositions for inhibiting influenza infection and/or replication based on the phenomenon of RNA interference (RNAi) well as systems for identifying effective siRNAs and shRNAs for inhibiting influenza virus and systems for studying influenza virus infective mechanisms. The invention also provides methods and compositions for inhibiting infection, pathogenicity and/or replication of other infectious agents, particularly those that infect cells that are directly accessible from outside the body, e.g., skin cells or mucosal cells. In addition, the invention provides compositions comprising an RNAi-inducing entity, e.g., an siRNA, shRNA, or RNAi-inducing vector targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for treatment of influenza.
摘要翻译：本发明提供了用于基于RNA干扰（RNAi）现象抑制流感感染和/或复制的方法和组合物以及用于鉴定用于抑制流感病毒的有效siRNA和shRNA以及用于研究流感病毒感染机制的系统的系统。本发明还提供用于抑制感染，致病性和/或其他感染因子的复制的方法和组合物，特别是感染可以从身体外部直接接近的细胞的感染，例如皮肤细胞或粘膜细胞的方法和组合物。此外，本发明提供了包含RNAi诱导实体的组合物，例如靶向流感病毒转录物的siRNA，shRNA或RNAi诱导载体以及各种递送试剂中的任何一种。本发明还包括使用该组合物治疗流感的方法。

3. 发明授权

US07501125B2 Vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent 失效
标题翻译：通过热休克蛋白融合蛋白诱导的体内CTL映射到离散的结构域，并且是CD4 + T细胞非依赖性的
公开(公告)号：US07501125B2
公开(公告)日：2009-03-10
申请号：US10885523
申请日：2004-07-01
申请人： Qian Huang , Joan F. L. Richmond , Bryan K. Cho , Deborah Pallister , Jianzhu Chen , Herman N. Eisen , Richard A. Young
发明人： Qian Huang , Joan F. L. Richmond , Bryan K. Cho , Deborah Pallister , Jianzhu Chen , Herman N. Eisen , Richard A. Young
IPC分类号： A61K38/00 , A61K39/00 , A61K39/385 , C07K14/00 , C07K14/005 , C07K14/195
CPC分类号： C07K14/35 , A61K39/00 , A61K47/62 , A61K47/6425 , A61K2039/57 , C07K2319/00
摘要： The present invention relates to a method of inducing a CD8+ CTL response to a molecule in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. In one embodiment, the present invention relates to a method of treating HIV in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. Also encompassed by the present invention is a method of inducing a CD4+ independent CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. The present invention also relates to a method of inducing a CD8+ CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. In addition, the present invention relates to a composition characterized by a portion of an ATP biding domain of an hsp joined to a molecule.
摘要翻译：本发明涉及对CD4 + T细胞缺陷的个体中的分子诱导CD8 + CTL应答的方法，其包括向所述个体施用连接到分子的hsp的hsp或一部分ATP结合结构域。在一个实施方案中，本发明涉及在CD4 + T细胞缺乏的个体中治疗HIV的方法，其包括向所述个体施用连接到分子的hsp的一个或多个ATP结合结构域的一部分。本发明还包括在个体中诱导CD4 +独立CTL应答的方法，其包括向所述个体施用连接到分子的hsp的ATP结合结构域的一部分。本发明还涉及在个体中诱导CD8 + CTL应答的方法，其包括向所述个体施用连接到该分子的hsp的ATP结合结构域的一部分。此外，本发明涉及一种组合物，其特征在于与分子连接的hsp的ATP结合域的一部分。

4. 发明授权

US06875435B2 In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent 失效
公开(公告)号：US06875435B2
公开(公告)日：2005-04-05
申请号：US09761534
申请日：2001-01-16
申请人： Qian Huang , Joan F. L. Richmond , Bryan K. Cho , Deborah Palliser , Jianzhu Chen , Herman N. Eisen , Richard A. Young
发明人： Qian Huang , Joan F. L. Richmond , Bryan K. Cho , Deborah Palliser , Jianzhu Chen , Herman N. Eisen , Richard A. Young
IPC分类号： A61K45/00 , A61K38/00 , A61K39/00 , A61K39/02 , A61K39/04 , A61K39/12 , A61K39/21 , A61K47/48 , A61P31/04 , A61P31/18 , A61P35/00 , A61P37/04 , C07K14/35 , A61K38/04 , A61K39/385
CPC分类号： C07K14/35 , A61K39/00 , A61K47/62 , A61K47/6425 , A61K2039/57 , C07K2319/00
摘要： The present invention relates to a method of inducing a CD8+ CTL response to a molecule in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. In one embodiment, the present invention relates to a method of treating HIV in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. Also encompassed by the present invention is a method of inducing a CD4+ independent CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. The present invention also relates to a method of inducing a CD8+ CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. In addition, the present invention relates to a composition characterized by a portion of an ATP biding domain of an hsp joined to a molecule.

5. 发明授权

US5580961A Heterodimeric T lymphocyte receptor subunit 失效
标题翻译：异二聚体T淋巴细胞受体亚单位
公开(公告)号：US5580961A
公开(公告)日：1996-12-03
申请号：US210326
申请日：1994-03-18
申请人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
发明人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
IPC分类号： C07K14/725 , C07K14/00
CPC分类号： C07K14/7051
摘要： Disclosed is a heterodimeric T lymphocyte receptor subunit. The subunit consists of variable, joining, constant, transmembrane, and cytoplasmic regions.The structure, amino acid, and nucleotide sequence of the lymphocyte receptor submit were determined using cDNA clones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressed and rearranged specifically in T cells and have significant sequence homologies to immunoglobulin V and C genes.T cell receptor subunits may be produced from the cDNA clones. The protein molecules may be further used for the production of T-cell clone specific antibodies.
摘要翻译：公开了异二聚体T淋巴细胞受体亚基。亚基由可变，连接，恒定，跨膜和胞质区组成。使用衍生自功能性鼠细胞毒性T淋巴细胞克隆的cDNA克隆测定淋巴细胞受体递交的结构，氨基酸和核苷酸序列。与这些cDNA相对应的基因在T细胞中特异性表达和重排，并且与免疫球蛋白V和C基因具有显着的序列同源性。 T细胞受体亚基可以从cDNA克隆产生。蛋白质分子可以进一步用于生产T细胞克隆特异性抗体。

6. 发明授权

US4970296A Heterodimeric T lymphocyte receptor 失效
标题翻译：异二聚体T淋巴细胞受体
公开(公告)号：US4970296A
公开(公告)日：1990-11-13
申请号：US385897
申请日：1989-07-27
申请人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
发明人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
IPC分类号： A61K38/00 , A61K39/00 , C07K14/725
CPC分类号： C07K14/7051 , A61K38/00 , A61K39/00
摘要： Disclosed is a heterodimeric T lymphocyte receptor comprising an alpha and a beta subunit. Each subunit consists of a signal peptide, variable, joining, constant, transmembrane, and cytoplasmic regions. The two subunits are connected by a disulfide bond between cysteine residues located between the constant and transmembrane region.The structure, amino acid, and nucleotide sequence of the lymphocyte receptor were determined using CDNA clones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressed and rearranged specifically in T cells and have significant sequence homologies to immunoglobulin V and C genes.Both the T cell receptor protein and its subunits may be produced from the cDNA clones. The protein molecules may be further used for the production of T-cell clone specific antibodies.
摘要翻译：公开了包含α和β亚基的异二聚体T淋巴细胞受体。每个亚基由信号肽，可变，连接，恒定，跨膜和细胞质区域组成。两个亚基通过位于恒定区和跨膜区之间的半胱氨酸残基之间的二硫键连接。使用衍生自功能性鼠细胞毒性T淋巴细胞克隆的CDNA克隆测定淋巴细胞受体的结构，氨基酸和核苷酸序列。与这些cDNA相对应的基因在T细胞中特异性表达和重排，并且与免疫球蛋白V和C基因具有显着的序列同源性。 T细胞受体蛋白及其亚基都可以从cDNA克隆产生。蛋白质分子可以进一步用于生产T细胞克隆特异性抗体。

7. 发明授权

US4921757A System for delayed and pulsed release of biologically active substances 失效
标题翻译：延迟和脉冲释放生物活性物质的系统
公开(公告)号：US4921757A
公开(公告)日：1990-05-01
申请号：US92554
申请日：1987-09-03
申请人： Margaret A. Wheatley , Robert S. Langer , Herman N. Eisen
发明人： Margaret A. Wheatley , Robert S. Langer , Herman N. Eisen
IPC分类号： A61K9/127 , A61K9/50 , A61K9/70
CPC分类号： A61K9/703 , A61K9/127 , A61K9/5026 , A61K9/5031 , A61K9/7084 , Y10S436/829 , Y10S514/963 , Y10S514/965 , Y10T428/2984
摘要： A system for controlled release both in vivo and in vitro of entrapped substances, either at a constant rate over a period of time or in discrete pulses, is disclosed. Biologically active substances, such as drugs, hormones, enzymes, genetic material, antigens including viruses, vaccines, or inorganic material such as dyes and nutrients, are entrapped in liposomes which are protected from the biological environment by encapsulation within semi-permeable microcapsules or a permeable polymeric matrix. Release of the entrapped substance into the surrounding environment is governed by the permeability of both the liposome and surrounding matrix to the substance. Permeability of the liposome is engineered by modifying the composition and method for making the liposomes, thereby producing liposomes which are sensitive to a specific stimuli such as temperature, pH, or light; or by including a phospholipase within some or all of the liposomes or the surrounding matrix; or by destabilizing the liposome to break down over a period of time; or by any combination of these features.
摘要翻译：公开了一种在一段时间内或以离散脉冲以恒定速率在体内和体外捕获的物质的系统。诸如药物，激素，酶，遗传物质，包括病毒的抗原，疫苗或诸如染料和营养素的无机材料的生物活性物质被包埋在通过包封在半渗透性微胶囊内的生物环境中保护的脂质体中可渗透聚合物基体。被截留的物质释放到周围环境中由脂质体和周围基质对物质的渗透性决定。通过改变制备脂质体的组合物和方法来改进脂质体的渗透性，从而产生对特定刺激如温度，pH或光敏感的脂质体; 或通过在一些或全部脂质体或周围基质中包含磷脂酶; 或通过不稳定脂质体在一段时间内分解; 或通过这些特征的任意组合。

8. 发明授权

US4543439A Production and use of monoclonal antibodies to phosphotyrosine-containing proteins 失效
标题翻译：生产和使用含磷酸酪氨酸蛋白的单克隆抗体
公开(公告)号：US4543439A
公开(公告)日：1985-09-24
申请号：US449355
申请日：1982-12-13
申请人： A. Raymond Frackelton, Jr. , Herman N. Eisen , Alonzo H. Ross
发明人： A. Raymond Frackelton, Jr. , Herman N. Eisen , Alonzo H. Ross
IPC分类号： C07K16/18 , G01N33/68 , C12N15/00 , G01N33/60
CPC分类号： G01N33/6842 , C07K16/18 , G01N33/68 , Y10S435/948
摘要： A hybridoma cell line is disclosed that secretes monoclonal antibodies which serve as a high titer, reproducible, biological reagent useful in biological/medical research for isolating and identifying phosphotyrosine-containing proteins. In addition, the antibodies have potential uses in diagnosis of a variety of diseases, including certain cancers. The antibodies, which have demonstrated affinity for a variety of molecules containing o-phosphotyrosine residues, were prepared using a synthetic analog, p-azobenzyl phosphonate (ABP) covalently linked to a carrier protein, as the antigen.
摘要翻译：公开了杂交瘤细胞系，其分泌用作生物/医学研究中用于分离和鉴定含磷酸酪氨酸的蛋白质的高滴度，可重复的生物试剂的单克隆抗体。此外，该抗体在诊断各种疾病（包括某些癌症）中具有潜在的用途。已经证实对含有o-磷酸酪氨酸残基的各种分子的亲和力的抗体是使用与载体蛋白共价连接的合成类似物对偶氮苄基膦酸酯（ABP）作为抗原制备的。

9. 发明申请

US20110112169A1 RNAi-BASED THERAPEUTICS FOR ALLERGIC RHINITIS AND ASTHMA 审中-公开
标题翻译：用于过敏性RHINITIS和ASTHMA的基于RNAi的治疗方法
公开(公告)号：US20110112169A1
公开(公告)日：2011-05-12
申请号：US12891626
申请日：2010-09-27
申请人： Jianzhu Chen , Herman N. Eisen , Qing Ge
发明人： Jianzhu Chen , Herman N. Eisen , Qing Ge
IPC分类号： A61K31/713 , C07H21/02 , A61K31/7105 , A61P11/00 , A61P11/06 , C12N15/63
CPC分类号： C12N15/113 , C12N15/111 , C12N15/1137 , C12N15/1138 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12N2320/32
摘要： The present invention provides compositions comprising one or more RNAi agents (e.g., siRNAs, shRNAs, or RNAi vectors) for the treatment of conditions and diseases mediated by (e.g., featuring IgE-mediated hypersensitivity), as well as systems for identifying RNAi agents effective for this purpose. The compositions are suitable for the treatment of allergic rhinitis and/or asthma. In certain embodiments of the invention the RNAi agent is targeted to a transcript that encodes a protein selected from the group consisting of the FCεRIα chain, the FCεRIβ chain, c-Kit, Lyn, Syk, ICOS, OX40L, CD40, CD80, CD86, Re1A, Re1B, 4-1BB ligand, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, CD83, SLAM, common γ chain, and COX-2. In addition, the invention provides RNAi agent/delivery agent compositions and methods of use. In certain embodiments of the invention compositions comprising an RNAi agent are delivered by the respiratory route.
摘要翻译：本发明提供包含用于治疗由（例如，特征为IgE介导的超敏反应）介导的病症和疾病的一种或多种RNAi剂（例如siRNA，shRNA或RNAi载体）的组合物，以及用于鉴定有效的RNAi剂的系统以此目的。该组合物适用于治疗过敏性鼻炎和/或哮喘。在本发明的某些实施方案中，所述RNAi试剂靶向编码选自下组的蛋白质的转录物：FC＆amp;RIα链，FC＆amp; RI＆bgr; 链，c-Kit，Lyn，Syk，ICOS，OX40L，CD40，CD80，CD86，Re1A，Re1B，4-1BB配体，TLR1，TLR2，TLR3，TLR4，TLR5，TLR6，TLR7，TLR8，TLR9，CD83，SLAM ，普通γ链和COX-2。此外，本发明提供RNAi剂/递送剂组合物和使用方法。在本发明的某些实施方案中，包含RNAi试剂的组合物通过呼吸途径递送。

10. 发明授权

US5977321A Heterodimeric T lymphocyte receptor subunit 失效
标题翻译：异二聚体T淋巴细胞受体亚单位
公开(公告)号：US5977321A
公开(公告)日：1999-11-02
申请号：US742539
申请日：1991-08-08
申请人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
发明人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
IPC分类号： C07K14/725 , C07K16/28
CPC分类号： C07K16/2809 , C07K14/7051
摘要： Disclosed is a heterodimeric T lymphocyte receptor subunit. The subunit consists of variable, joining, constant, transmembrane, and cytoplasmic regions.The structure, amino acid, and nucleotide sequence of the lymphocyte receptor subunit were determined using cDNA clones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressed and rearranged specifically in T cells and have significant sequence homologies to immunoglobulin V and C genes.T cell receptor subunits may be produced from the cDNA clones. The protein molecules may be further used for the production of T-cell clone specific antibodies.
摘要翻译：公开了异二聚体T淋巴细胞受体亚基。亚基由可变，连接，恒定，跨膜和胞质区组成。使用衍生自功能性鼠细胞毒性T淋巴细胞克隆的cDNA克隆测定淋巴细胞受体亚基的结构，氨基酸和核苷酸序列。与这些cDNA相对应的基因在T细胞中特异性表达和重排，并且与免疫球蛋白V和C基因具有显着的序列同源性。 T细胞受体亚基可以从cDNA克隆产生。蛋白质分子可以进一步用于生产T细胞克隆特异性抗体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式